• #13 : Rybrevant & Lazcluze: A New Era in Lung Cancer Treatment

  • Jan 10 2025
  • Length: 17 mins
  • Podcast

#13 : Rybrevant & Lazcluze: A New Era in Lung Cancer Treatment

Listen for free

View show details

  • Summary

  • Johnson & Johnson's Rybrevant and Lazcluze drug combination shows significant improvement in overall survival for patients with EGFR-mutated non-small cell lung cancer compared to the current standard treatment, Tagrisso. This new treatment targets a resistance pathway, offering a potential lifeline for many patients, although it requires infusions and has potential side effects. Full trial results are forthcoming, and the company anticipates substantial sales. The development highlights advances in precision medicine for lung cancer.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about #13 : Rybrevant & Lazcluze: A New Era in Lung Cancer Treatment

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available